Evaluation of the tolerability of sustained-release morphine for patients with interstitial lung disease

Phase 2

Recruiting

• Conditions: interstitial pneumonia

• Registration Number: JPRN-jRCTs041230028
• Lead Sponsor: Suda Takafumi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-30
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

1. Patients who are 20 years old or older at the time of consent
2. Patients with a diagnosis of interstitial pneumonia
3. Patients with dyspnea (mMRC >= 3) despite standard therapy for the primary disease
4. All of the following laboratory values within 28 days prior to enrollment
AST =< 100 IU/L, ALT =< 100 IU/L, T-Bil =< 2.0 mg/dL, serum Cre =< 2.0 mg/dL,
SpO2 at rest >= 90% (oxygen can be administered)
5. Patients with a prognosis of more than 1 month
6. Patients who can answer and fill in the questionnaire by themselves
7. Patients whose written consent has been obtained from the patient

Exclusion Criteria

1. Patients with severe respiratory depression
2. Patients with bronchial asthma attacks
3. Patients with severe hepatic impairment
4. Patients with physical findings suggestive of cardiac failure secondary to chronic pulmonary disease
5. Patients in a convulsive state
6. Patients with acute alcohol intoxication
7. Patients with hypersensitivity to opium alkaloids
8. Patients with hemorrhagic colitis
9. Patients receiving nalmefene hydrochloride hydrate or within 1 week of discontinuation of nalmefene hydrochloride hydrate
10. Patients with bacterial diarrhea
11. Patients with PaCO2 >= 60 Torr
12. Patients with symptoms of acute respiratory failure (e.g., bacterial pneumonia, acute exacerbation of interstitial pneumonia) within 1 months prior to enrollment
13. Patients with active infection-causing dyspnea
14. Patients with lung cancer complications causing dyspnea
15. Patients with complications of pulmonary thromboembolism
16. Patients on a ventilator
17. Patients on opioid preparations (except codeine phosphate hydrate less than 60 mg/day)
18. Patients with drug abuse, dependence, or a history of drug abuse or dependence
19. Pregnant women, lactating women, or patients who may be pregnant
20. Other patients deemed ineligible by the principal investigator or sub-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified